NGS MRD Negativity on Day 28 after Brexu Cel in Adults with R/R ALL Is Associated with Favorable Progression Free SurvivalYannis K. Valtis, Shabaz Malik, David Nemirovsky et al.|Blood|2024Cited by 3
CAR HEMATOTOX independently predicts outcomes after CD19 CAR-T therapy for acute lymphoblastic leukemiaYannis K. Valtis, Jae H. Park, Amy Zhang et al.|Blood Advances|2025Cited by 3
NGS MRD Negativity on Day 28 after Brexu Cel in Adults with R/R ALL Is Associated with Favorable Progression Free SurvivalYannis K. Valtis, Aaron C. Logan, David Nemirovsky et al.|Transplantation and Cellular Therapy|2025Cited by 0
Real-world administration blinatumomab in the outpatient setting: Toxicity outcomes and healthcare utilizationYannis K. Valtis, Evan C. Chen, Benjamin Frost et al.|Blood|2025Cited by 0
Prognosis in adults with ph-positive B-ALL in first complete remission without minimal residual disease after blinatumomab consolidation is influenced by minimal residual disease (≥10-4) pre-blinatumomabBenjamin Frost, Evan C. Chen, Yannis K. Valtis et al.|Blood|2025Cited by 0